ReCor Medical raised the money in a series D round led by healthcare group Otsuka Holdings that will support a trial study for its hypertension treatment device.
US-based medical device maker ReCor Medical raised approximately $15m on Friday in a series D round led by Otsuka Holdings, the parent company the Otsuka group of healthcare companies.
Venture capital firm Sofinnova Partners also took part in the round, which was announced concurrently with news of a new randomised, controlled trial of ReCor’s lead product, Paradise Renal Denervation System.
Paradise uses ultrasound to treat resistant hypertension, a condition whereby blood pressure remains is elevated too highly.
The new study,…
